Abstract：
METHODS: The purpose of this American Gastroenterological Association (AGA) Institute Clinical Practice Update (CPU) Commentary is to discuss the risks of various malignancies in patients with inflammatory bowel diseases (IBD) and the impact of the available medical therapies on these risks. The CPU will also guide the approach to the patient with IBD who develops a malignancy or the patient with a history of cancer in terms of IBD medication management.
METHODS: This CPU was commissioned and approved by the AGA Institute CPU committee and the AGA Governing Board to provide timely guidance on a topic of high clinical importance to the AGA membership and underwent internal peer review by the CPU committee and external peer review through standard procedures of Clinical Gastroenterology and Hepatology. This communication incorporates important and recently published studies in the field, and it reflects the experiences of the authors who are experts in the diagnosis and management of IBD.
METHODS: This CPU was commissioned and approved by the AGA Institute CPU committee and the AGA Governing Board to provide timely guidance on a topic of high clinical importance to the AGA membership and underwent internal peer review by the CPU committee and external peer review through standard procedures of Clinical Gastroenterology and Hepatology. This communication incorporates important and recently published studies in the field, and it reflects the experiences of the authors who are experts in the diagnosis and management of IBD.
摘要：
方法：美国胃肠病协会（AGA）研究所临床实践更新（CPU）评论的目的是讨论炎症性肠病（IBD）患者各种恶性肿瘤的风险以及可用药物治疗对这些风险的影响。CPU还将在IBD药物管理方面指导对发展为恶性肿瘤的IBD患者或具有癌症史的患者的方法。
方法：该CPU由AGA研究所CPU委员会和AGA理事会委托和批准，以就对AGA成员具有高临床重要性的主题提供及时指导，并通过内部同行评审由CPU委员会和外部同行评审通过临床胃肠病学和肝病学的标准程序。本通讯包含了该领域的重要和最近发表的研究，它反映了作者在IBD诊断和管理方面的经验。
方法：该CPU由AGA研究所CPU委员会和AGA理事会委托和批准，以就对AGA成员具有高临床重要性的主题提供及时指导，并通过内部同行评审由CPU委员会和外部同行评审通过临床胃肠病学和肝病学的标准程序。本通讯包含了该领域的重要和最近发表的研究，它反映了作者在IBD诊断和管理方面的经验。
